SK279567B6 - Použitie flupirtínu alebo jeho terapeuticky zhodno - Google Patents

Použitie flupirtínu alebo jeho terapeuticky zhodno Download PDF

Info

Publication number
SK279567B6
SK279567B6 SK2101-91A SK210191A SK279567B6 SK 279567 B6 SK279567 B6 SK 279567B6 SK 210191 A SK210191 A SK 210191A SK 279567 B6 SK279567 B6 SK 279567B6
Authority
SK
Slovakia
Prior art keywords
flupirtine
acid
muscle
solution
compound
Prior art date
Application number
SK2101-91A
Other languages
English (en)
Slovak (sk)
Inventor
Michael Lobisch
Ralph Venhaus
Bernd Nickel
Istvan Szelenyi
J�Rgen Engel
Peter Emig
Original Assignee
Asta Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Aktiengesellschaft filed Critical Asta Pharma Aktiengesellschaft
Publication of SK279567B6 publication Critical patent/SK279567B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK2101-91A 1990-07-14 1991-07-08 Použitie flupirtínu alebo jeho terapeuticky zhodno SK279567B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (he) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
SK279567B6 true SK279567B6 (sk) 1999-01-11

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
SK2101-91A SK279567B6 (sk) 1990-07-14 1991-07-08 Použitie flupirtínu alebo jeho terapeuticky zhodno

Country Status (30)

Country Link
US (2) US5162346A (he)
EP (2) EP0659410B1 (he)
KR (1) KR0182811B1 (he)
CN (1) CN1070700C (he)
AT (2) ATE133564T1 (he)
AU (1) AU634073B2 (he)
CA (1) CA2046943C (he)
CZ (1) CZ280879B6 (he)
DE (3) DE4122166A1 (he)
DK (2) DK0659410T3 (he)
EG (1) EG19814A (he)
ES (2) ES2082887T3 (he)
GR (1) GR3019179T3 (he)
HR (1) HRP920667B1 (he)
HU (1) HU206973B (he)
IE (1) IE74688B1 (he)
IL (1) IL98810A (he)
IN (1) IN172468B (he)
LT (1) LT3593B (he)
LV (1) LV10048B (he)
MC (1) MC2272A1 (he)
MX (1) MX9100160A (he)
NO (1) NO912758L (he)
NZ (1) NZ238940A (he)
PT (1) PT98291B (he)
RO (1) RO108220B1 (he)
RU (1) RU2070408C1 (he)
SI (1) SI9111227B (he)
SK (1) SK279567B6 (he)
ZA (1) ZA915466B (he)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE160696T1 (de) * 1992-03-11 1997-12-15 Asta Medica Ag Tabletten, granulate und pellets mit hohem gehalt an wirkstoffen für hochkonzentrierte, feste darreichungsformen
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
SK1712002A3 (en) * 1999-08-03 2003-03-04 Awd Pharma Gmbh & Co Kg Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
CA2650853A1 (en) * 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
ES2420960T3 (es) * 2006-08-23 2013-08-28 Valeant Pharmaceuticals International Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ES2375417T3 (es) * 2006-11-28 2012-02-29 Valeant Pharmaceuticals International Análogos 1,4-diamino bicíclicos de retigabina como moduladores de los canales de potasio.
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
MX2010001171A (es) * 2007-08-01 2010-03-01 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sistema dopaminergico.
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
ATE43789T1 (de) * 1985-02-23 1989-06-15 Asta Pharma Ag Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A (fi) * 1985-06-28 1986-12-29 Degussa Synergistisk kombination av flupirtin och 4-acetamido-fenol.

Also Published As

Publication number Publication date
ES2164111T3 (es) 2002-02-16
AU634073B2 (en) 1993-02-11
EG19814A (en) 1996-02-29
KR920002147A (ko) 1992-02-28
IE912451A1 (en) 1992-01-15
DE4122166A1 (de) 1992-01-16
NO912758L (no) 1992-01-15
CA2046943A1 (en) 1992-01-15
RU2070408C1 (ru) 1996-12-20
ATE206919T1 (de) 2001-11-15
ATE133564T1 (de) 1996-02-15
HU206973B (en) 1993-03-01
GR3019179T3 (en) 1996-06-30
PT98291A (pt) 1992-05-29
HUT59313A (en) 1992-05-28
EP0659410A2 (de) 1995-06-28
US5284861A (en) 1994-02-08
IL98810A0 (en) 1992-07-15
RO108220B1 (ro) 1994-03-31
US5162346A (en) 1992-11-10
HRP920667A2 (en) 1996-10-31
CS210191A3 (en) 1992-02-19
MC2272A1 (fr) 1993-06-23
HU912359D0 (en) 1991-12-30
EP0467164A3 (en) 1992-04-15
ES2082887T3 (es) 1996-04-01
HRP920667B1 (en) 1998-06-30
CN1070700C (zh) 2001-09-12
EP0659410A3 (de) 1995-10-25
KR0182811B1 (ko) 1999-05-01
NZ238940A (en) 1997-05-26
LTIP919A (en) 1995-03-27
CA2046943C (en) 1996-03-12
CZ280879B6 (cs) 1996-04-17
LT3593B (en) 1995-12-27
SI9111227B (sl) 2000-12-31
SI9111227A (en) 1995-06-30
DE59109222D1 (de) 2001-11-22
EP0659410B1 (de) 2001-10-17
LV10048B (en) 1995-06-20
EP0467164A2 (de) 1992-01-22
IN172468B (he) 1993-08-14
CN1058716A (zh) 1992-02-19
EP0467164B1 (de) 1996-01-31
DK0659410T3 (da) 2001-12-27
MX9100160A (es) 1992-02-28
LV10048A (lv) 1994-05-10
ZA915466B (en) 1992-04-29
IE74688B1 (en) 1997-07-30
DK0467164T3 (da) 1996-03-04
AU8040391A (en) 1992-01-16
DE59107331D1 (de) 1996-03-14
NO912758D0 (no) 1991-07-12
PT98291B (pt) 1999-01-29
IL98810A (he) 1996-01-19

Similar Documents

Publication Publication Date Title
SK279567B6 (sk) Použitie flupirtínu alebo jeho terapeuticky zhodno
CA2009593C (en) Medicament containing dihydrolipoic acid as active substance
AU2011270726B2 (en) Niacin mimetics, and methods of use thereof
JP2991733B2 (ja) 乾癬疾患を抑制するための薬剤及びその製法
JP5925770B2 (ja) ナイアシン模倣体、およびその使用方法
IE870973L (en) Synergistic combination product
DD244293A5 (de) Verfahren zur herstellung eines arzneimittels
DE69427551T2 (de) Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
US5750534A (en) Nalbuphine esters having long acting analgesic action and method of use
CH672735A5 (he)
DE69006863T2 (de) Ein piperidinylalkanolantihistaminikum enthaltende flüssige Arzneizubereitungen.
EP0492747B1 (en) Pharmaceutical preparation for topical application
JP3141051B2 (ja) 抗動脈硬化剤
JPS58164507A (ja) ジベンゾシクロヘプテニリデン類による免疫変化剤
DE4333794A1 (de) Neue Acetyl-Salicylsäure-Derivate zur Bekämpfung von Entzündungs- und Schmerzzuständen sowie zur Thromboseprophylaxe und -terapie
JPS61204124A (ja) 冠血管拡張剤
JPH0532627A (ja) 筋肉痙攣により帰因するか又は筋肉痙攣の結果である疾病及び症候群を治療するための医薬品及びその製法
JPH03287537A (ja) 抗動脈硬化症剤
JPS61172820A (ja) カルシウム拮抗剤
IE84029B1 (en) Use of the compound flupirtin for the preparation of a medicament against muscle bracing
JPH06145055A (ja) 局所投与用医薬
IL100595A (en) Pharmaceutical preparation for topical application comprising a clonixinate salt
IE920090A1 (en) Pharmaceutical preparation for topical application

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20110708